Bhatt’s study, "Dupilumab for COPD with Type 2 Inflammation Indicated by Eosinophil Counts,” was recently published in The New England Journal of Medicine. Bhatt and colleagues conducted a multicenter ...

Dupilumab significantly reduced exacerbations and improved lung function in adults with uncontrolled chronic obstructive pulmonary disease (COPD) and type 2 inflammation, based on data from more than ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. “Type 2 myocardial infarction occurs due to a mismatch ...

Chronic obstructive pulmonary disease patients with type 2 inflammation may soon gain access to a new drug -- dupilumab -- that showed rapid and sustained improvements in patients in a pivotal Phase 3 ...

Priority Review granted based on positive results from two Phase 3 trials If approved, Dupixent would be the only biologic therapy for COPD and the first new treatment approach for the disease in more ...

Chronic obstructive pulmonary disease patients with type 2 inflammation saw rapid and sustained improvements in their disease after treatment with the monoclonal antibody dupilumab, according to a ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. The phase 3 BOREAS trial included adults with ...

Inhalers and nebulizers are necessary when managing chronic obstructive pulmonary disease (COPD). Both are designed to deliver medication directly to the lungs, which helps in reducing symptoms, ...